Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study
Open Access
- 31 January 2022
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 82 (1) , 12-19
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Cancerfonden
- Vetenskapsrådet
This publication has 18 references indexed in Scilit:
- Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI ProjectEuropean Urology Focus, 2017
- The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy populationScientific Reports, 2016
- Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic studyThe Lancet Oncology, 2015
- Magnetic Resonance Imaging–targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysisEuropean Urology, 2015
- Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC DataJNCI: Journal of the National Cancer Institute, 2014
- Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011European Urology, 2013
- Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based StudyEuropean Urology, 2013
- Quality-of-Life Effects of Prostate-Specific Antigen ScreeningNew England Journal of Medicine, 2012
- Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerBritish Journal of Cancer, 2009
- Swedish population health-related quality of life results using the EQ-5DQuality of Life Research, 2001